Case 6

Adam R et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 2006;244(6):897-907. Abstract

Boccardo F et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 1994;5(4):337-42. Abstract

Caralt M et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol 2008;15(10):2804-10. Abstract

D’Annibale M et al. Liver metastases from breast cancer: The role of surgical treatment. Hepatogastroenterology 2005;52(66):1858-62. Abstract

Jakobs TF et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2008;[Epub ahead of print]. Abstract

Marcom PK et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102(1):43-9. Abstract

Selzner M et al. Liver metastases from breast cancer: Long-term survival after curative resection. Surgery 2000;127(4):383-9. Abstract

Sofocleous CT et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007;189(4):883-9. Abstract

Vlastos G et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 2004;11(9):869-74. Abstract

Case 7

Blanchard DK et al. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008;247(5):732-8. Abstract

Fields RC et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007;14(12):3345-51. Abstract

Gnerlich J et al. Patient and tumor characteristics associated with primary tumor resection in women with Stage IV breast cancer: Analysis of 1988-2003 SEER data. Breast J 2008;14(6):538- 42. Abstract

Gnerlich J et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: Analysis of the 1988-2003 SEER data. Ann Surg Oncol 2007;14(8):2187-94. Abstract

Hazard HW et al. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 2008;113(8):2011-9. Abstract

Johnston S et al. Lapatinib combined with letrozole vs letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): First results from the EGF30008 Trial. SABCS 2008;Abstract 46.

Khan SA. Primary tumor resection in stage IV breast cancer: Consistent benefit, or consistent bias? Ann Surg Oncol 2007;14(12):3285-7. Abstract

Rao R et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008;15(6):1696-702. Abstract

Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract

Case 8

Chia S et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 2008;26(10):1664-70. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract

Ingle JN et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24(7):1052-6. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Paridaens RJ et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26(30):4883-90. Abstract

Perey L et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007;18(1):64-9. Abstract

Case 9

Albain KS et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26(24):3950-7. Abstract

Danso MA et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Proc ASCO 2008;Abstract 1075.

Gluck S et al. Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC). Proc ASCO 2008;Abstract 1089.

Gradishar et al. Randomized comparison of weekly or every 3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2007;Abstract 1032.

Hart LL et al. A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): Preliminary results. Proc ASCO 2008;Abstract 575.

Miles D et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc ASCO 2008; Abstract LBA1011.

Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76. Abstract

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Roy V et al. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane^®) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2008;[Epub ahead of print]. Abstract

Sledge G et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Proc ASCO 2007;Abstract 1013.

Vici P et al. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. Oncology 2008;75(3-4):175-81. Abstract

Vukelja SJ et al. Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC). Proc ASCO 2008;Abstract 1082.

Case 10

Carey LA et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Proc ASCO 2008;Abstract 1009.

Chia JW et al. Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/ carboplatin combination chemotherapy. Proc ASCO 2007;Abstract 1086.

Lin NU et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 2008;113(10):2638-45. Abstract

O’Shaughnessy J et al. Triple negative breast cancer: A phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. San Antonio Breast Cancer Symposium 2008;Abstract 2120.

Rugo HS et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: A pooled analysis of patients from two large phase III clinical studies. San Antonio Breast Cancer Symposium 2008;Abstract 3057.

Schneider BP et al. Triple-negative breast cancer: Risk factors to potential targets. Clin Cancer Res 2008;14(24):8010-8. Abstract

Tan AR, Swain SM. Therapeutic strategies for triple-negative breast cancer. Cancer J 2008;14(6):343-51. Abstract